MedTrace Logo

L19IL2/L19TNF in Skin Cancer Patients

NCT05329792 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2023-10-06

No results posted yet for this study

Summary

Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention.

Conditions

  • BCC - Basal Cell Carcinoma
  • SCC - Squamous Cell Carcinoma
  • Merkel Cell Carcinoma
  • Keratoacanthoma of Skin
  • Malignant Adnexal Tumors of the Skin (MATS)
  • Tumors From Cutaneous T-cell Lymphoma (CTCL)
  • Kaposi Sarcoma

Interventions

DRUG

L19IL2/L19TNF

Patients will be treated with a mixture of L19IL2 and L19TNF once weekly for 4 consecutive weeks

Sponsors & Collaborators

  • Philogen S.p.A.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-09
Primary Completion
2024-06-30
Completion
2024-12-31

Countries

  • France
  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05329792 on ClinicalTrials.gov